CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration

The causes of age-related macular degeneration (AMD) are not well understood. Due to demographic shifts in the industrialized world a growing number of people will develop AMD in the coming decades. To develop treatments it is essential to characterize the disease's pathogenic process. Over the past few years, numerous studies have focused on the role of chemotactic cytokines, also known as chemokines. Certain chemokines, such as CCL2 and CX3CL1, appear to be crucial in subretinal microglia and macrophage accumulation observed in AMD, and participate in the development of retinal degeneration as well as in choroidal neovascularization. This paper reviews the possible implications of CCL2 and CX3CL1 signaling in AMD. Expression patterns, single nucleotide polymorphisms (SNPs) association studies, chemokine and chemokine receptor knockout models are discussed. Future AMD treatments could target chemokines and/or their receptors

Rôles des chimiokines dans le développement de la dégénérescence maculaire liée à l’âge

International audienceRole of chemokines in the development of age-related macular degeneration. Age-related macular degeneration (AMD) is the main cause of irreversible blindness in industrialized nations. Recent research has emphasized the importance of inflam-matory processes in pathogenesis of this disease. Chemotactic cytokines also named chemokines are important mediators of inflammation and might have a role in development of this disease. They appear to be crucial in the subretinal microglia / macrophage accumulation observed in AMD and may participate in the development of retinal degeneration and in choroidal neovascularization. This paper reviews the possible implication of chemokines in the development of AMD.La dégénérescence maculaire liéeà l'âge (DMLA) est la principale cause de cécité irréversible dans les pays industrialisés. Lesétudes récentes mettent en exergue l'importance des processus inflammatoires dans le développement de la maladie. Les cytokines chimiotactiques, dénommées chimiokines, qui apparaissent comme des médiateurs importants de l'inflammation, pourraient jouer un rôle dans le développement de la DMLA. Plus particulièrement, elles semblent indispensables dans le processus d'accumulation des microglies/macrophages dans l'espace sous-rétinien observé au cours de la DMLA. Elles pourraient par conséquent partici-per au développement de la dégénérescence rétinienne et de la néovascularisation choroïdienne. Dans cette revue, nous décrirons l'implication des chimiokines et de leurs récepteurs dans le développement de la DMLA

Therapeutic exercise attenuates neutrophilic lung injury and skeletal muscle wasting

Early mobilization of critically ill patients with the acute respiratory distress syndrome (ARDS) has emerged as a therapeutic strategy that improves patient outcomes, such as the duration of mechanical ventilation and muscle strength. Despite the apparent efficacy of early mobility programs, their use in clinical practice is limited outside of specialized centers and clinical trials. To evaluate the mechanisms underlying mobility therapy, we exercised acute lung injury (ALI) mice for 2 days after the instillation of lipopolysaccharides into their lungs. We found that a short duration of moderate intensity exercise in ALI mice attenuated muscle ring finger 1 (MuRF1)?mediated atrophy of the limb and respiratory muscles and improved limb muscle force generation. Exercise also limited the influx of neutrophils into the alveolar space through modulation of a coordinated systemic neutrophil chemokine response. Granulocyte colony-stimulating factor (G-CSF) concentrations were systemically reduced by exercise in ALI mice, and in vivo blockade of the G-CSF receptor recapitulated the lung exercise phenotype in ALI mice. Additionally, plasma G-CSF concentrations in humans with acute respiratory failure (ARF) undergoing early mobility therapy showed greater decrements over time compared to control ARF patients. Together, these data provide a mechanism whereby early mobility therapy attenuates muscle wasting and limits ongoing alveolar neutrophilia through modulation of systemic neutrophil chemokines in lung-injured mice and humans.Fil: Files, D. Clark. School Of Medicine; Estados UnidosFil: Liu, Chun. School Of Medicine; Estados UnidosFil: Pereyra, Andrea Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner". Universidad Nacional de la Plata. Facultad de Ciencias Médicas. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner"; ArgentinaFil: Wang, Zhong Min. University Wake Forest; Estados Unidos. School Of Medicine; Estados UnidosFil: Aggarwal, Neil. Johns Hopkins Asthma And Allergy Center; Estados UnidosFil: D´Alessio, Franco. Johns Hopkins Asthma And Allergy Center; Estados UnidosFil: Garibaldi, Brian T.. Johns Hopkins Asthma and Allergy Center; Estados UnidosFil: Mock, Jason R.. Johns Hopkins Asthma and Allergy Center; Estados UnidosFil: Singer, Benjamin D.. Johns Hopkins Asthma and Allergy Center; Estados UnidosFil: Feng, Xin. Wake Forest School of Medicine; Estados UnidosFil: Yammani, Raghunatha R.. Wake Forest School of Medicine; Estados UnidosFil: Zhang, Tan. Wake Forest School of Medicine; Estados UnidosFil: Lee, Amy L.. Wake Forest School of Medicine; Estados UnidosFil: Philpott, Sydney. Wake Forest School of Medicine; Estados UnidosFil: Lussier, Stephanie. Wake Forest School of Medicine; Estados UnidosFil: Purcell, Lina. Wake Forest School of Medicine; Estados UnidosFil: Chou, Jeff. Wake Forest School of Medicine; Estados UnidosFil: Seeds, Michael. Wake Forest School of Medicine; Estados UnidosFil: King, Landon S.. Johns Hopkins Asthma and Allergy Center; Estados UnidosFil: Morris, Peter E.. Wake Forest School of Medicine; Estados UnidosFil: Delbono, Osvaldo. School Of Medicine; Estados Unido

A Family of Helminth Molecules that Modulate Innate Cell Responses via Molecular Mimicry of Host Antimicrobial Peptides

Over the last decade a significant number of studies have highlighted the central role of host antimicrobial (or defence) peptides in modulating the response of innate immune cells to pathogen-associated ligands. In humans, the most widely studied antimicrobial peptide is LL-37, a 37-residue peptide containing an amphipathic helix that is released via proteolytic cleavage of the precursor protein CAP18. Owing to its ability to protect against lethal endotoxaemia and clinically-relevant bacterial infections, LL-37 and its derivatives are seen as attractive candidates for anti-sepsis therapies. We have identified a novel family of molecules secreted by parasitic helminths (helminth defence molecules; HDMs) that exhibit similar biochemical and functional characteristics to human defence peptides, particularly CAP18. The HDM secreted by Fasciola hepatica (FhHDM-1) adopts a predominantly α-helical structure in solution. Processing of FhHDM-1 by F. hepatica cathepsin L1 releases a 34-residue C-terminal fragment containing a conserved amphipathic helix. This is analogous to the proteolytic processing of CAP18 to release LL-37, which modulates innate cell activation by classical toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS). We show that full-length recombinant FhHDM-1 and a peptide analogue of the amphipathic C-terminus bind directly to LPS in a concentration-dependent manner, reducing its interaction with both LPS-binding protein (LBP) and the surface of macrophages. Furthermore, FhHDM-1 and the amphipathic C-terminal peptide protect mice against LPS-induced inflammation by significantly reducing the release of inflammatory mediators from macrophages. We propose that HDMs, by mimicking the function of host defence peptides, represent a novel family of innate cell modulators with therapeutic potential in anti-sepsis treatments and prevention of inflammation

Départ en congé le 4 novembre 1790 de M. Auvynet, annoncée lors de la séance du 3 novembre 1790

Auvynet Charles-Joseph. Départ en congé le 4 novembre 1790 de M. Auvynet, annoncée lors de la séance du 3 novembre 1790. In: Archives Parlementaires de 1787 à 1860 - Première série (1787-1799) Tome XX - Du 23 octobre au 26 novembre 1790. Paris : Librairie Administrative P. Dupont, 1885. p. 252

Départ en congé le 4 novembre 1790 de M. Auvynet, annoncée lors de la séance du 3 novembre 1790

Auvynet Charles-Joseph. Départ en congé le 4 novembre 1790 de M. Auvynet, annoncée lors de la séance du 3 novembre 1790. In: Archives Parlementaires de 1787 à 1860 - Première série (1787-1799) Tome XX - Du 23 octobre au 26 novembre 1790. Paris : Librairie Administrative P. Dupont, 1885. p. 252

Des peptides immunomodulateurs aux peptides opioïdes de la peau de rainettes latino-américaines (ou l'originalité d'un modèle)

La peau de grenouilles sécrète un grand nombre de peptides aux propriétés pharmacologiques remarquables. Ces peptides, produits en grande quantité, sont souvent similaires à ceux utilisés par les mammifères dans leur système nerveux central et endocrinien. Les peptides de grenouille représentent donc un modèle original pour l étude de peptides similaires chez l Homme. Nous avons mis en évidence la présence, dans la peau de Pachymedusa dacnicolor et Phyllomedusa sauvagei, de peptides ayant des propriétés immunomodulatrices sur les cellules immunitaires humaines ainsi que l importance de la structure de type beta-amyloïdogénique pour l activité biologique de l un de ces peptides, la dermaseptine S9. Nous avons enfin localisé dans les granules des glandes séreuses de la peau de Phyllomedusa bicolor, un peptide antimicrobien, la dermaseptine B2, et un peptide opioïde, la deltorphine I, très similaire aux opioïdes de mammifères mais contenant un acide aminé D dans sa séquence.PARIS-BIUSJ-Thèses (751052125) / SudocPARIS-BIUSJ-Physique recherche (751052113) / SudocSudocFranceF

Retour de congés de M. Auvynet, lors de la séance du 9 mars 1791

Auvynet Charles-Joseph. Retour de congés de M. Auvynet, lors de la séance du 9 mars 1791. In: Archives Parlementaires de 1787 à 1860 - Première série (1787-1799) Tome XXIII - Du 6 février 1791 au 9 mars 1791. Paris : Librairie Administrative P. Dupont, 1886. p. 752